Laura L Hammitt1, Ron Dagan1, Yuan Yuan1, Manuel Baca Cots1, Miroslava Bosheva1, Shabir A Madhi1, William J Muller1, Heather J Zar1, Dennis Brooks1, Amy Grenham1, Ulrika Wählby Hamrén1, Vaishali S Mankad1, Pin Ren1, Therese Takas1, Michael E Abram1, Amanda Leach1, M Pamela Griffin1, Tonya Villafana1. 1. From the Department of International Health, Johns Hopkins University, Baltimore (L.L.H.), and AstraZeneca, Gaithersburg (Y.Y., D.B., A.G., P.R., T.T., M.E.A., A.L., M.P.G., T.V.) - both in Maryland; the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel (R.D.); Quirónsalud Málaga Hospital, Malaga, Spain (M.B.C.); University Multiprofile Hospital for Active Treatment, St. George Medical University, Plovdiv, Bulgaria (M.B.); the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.), and the Department of Paediatrics and Child Health, Red Cross Children's Hospital, and the Medical Research Council Unit on Child and Adolescent Health, University of Cape Town, Cape Town (H.J.Z.) - all in South Africa; Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago (W.J.M.); AstraZeneca, Gothenburg, Sweden (U.W.H.); and AstraZeneca, Durham, NC (V.S.M.).
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS: We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or placebo before the start of an RSV season. The primary efficacy end point was medically attended RSV-associated lower respiratory tract infection through 150 days after the injection. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after the injection. RESULTS: A total of 1490 infants underwent randomization: 994 were assigned to the nirsevimab group and 496 to the placebo group. Medically attended RSV-associated lower respiratory tract infection occurred in 12 infants (1.2%) in the nirsevimab group and in 25 infants (5.0%) in the placebo group; these findings correspond to an efficacy of 74.5% (95% confidence interval [CI], 49.6 to 87.1; P<0.001) for nirsevimab. Hospitalization for RSV-associated lower respiratory tract infection occurred in 6 infants (0.6%) in the nirsevimab group and in 8 infants (1.6%) in the placebo group (efficacy, 62.1%; 95% CI, -8.6 to 86.8; P = 0.07). Among infants with data available to day 361, antidrug antibodies after baseline were detected in 58 of 951 (6.1%) in the nirsevimab group and in 5 of 473 (1.1%) in the placebo group. Serious adverse events were reported in 67 of 987 infants (6.8%) who received nirsevimab and in 36 of 491 infants (7.3%) who received placebo. CONCLUSIONS: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection. (Funded by MedImmune/AstraZeneca and Sanofi; MELODY ClinicalTrials.gov number, NCT03979313.).
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS: We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or placebo before the start of an RSV season. The primary efficacy end point was medically attended RSV-associated lower respiratory tract infection through 150 days after the injection. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after the injection. RESULTS: A total of 1490 infants underwent randomization: 994 were assigned to the nirsevimab group and 496 to the placebo group. Medically attended RSV-associated lower respiratory tract infection occurred in 12 infants (1.2%) in the nirsevimab group and in 25 infants (5.0%) in the placebo group; these findings correspond to an efficacy of 74.5% (95% confidence interval [CI], 49.6 to 87.1; P<0.001) for nirsevimab. Hospitalization for RSV-associated lower respiratory tract infection occurred in 6 infants (0.6%) in the nirsevimab group and in 8 infants (1.6%) in the placebo group (efficacy, 62.1%; 95% CI, -8.6 to 86.8; P = 0.07). Among infants with data available to day 361, antidrug antibodies after baseline were detected in 58 of 951 (6.1%) in the nirsevimab group and in 5 of 473 (1.1%) in the placebo group. Serious adverse events were reported in 67 of 987 infants (6.8%) who received nirsevimab and in 36 of 491 infants (7.3%) who received placebo. CONCLUSIONS: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection. (Funded by MedImmune/AstraZeneca and Sanofi; MELODY ClinicalTrials.gov number, NCT03979313.).
Authors: Giuseppe Pantaleo; Bruno Correia; Craig Fenwick; Victor S Joo; Laurent Perez Journal: Nat Rev Drug Discov Date: 2022-06-20 Impact factor: 112.288
Authors: You Li; Xin Wang; Dianna M Blau; Mauricio T Caballero; Daniel R Feikin; Christopher J Gill; Shabir A Madhi; Saad B Omer; Eric A F Simões; Harry Campbell; Ana Bermejo Pariente; Darmaa Bardach; Quique Bassat; Jean-Sebastien Casalegno; Giorgi Chakhunashvili; Nigel Crawford; Daria Danilenko; Lien Anh Ha Do; Marcela Echavarria; Angela Gentile; Aubree Gordon; Terho Heikkinen; Q Sue Huang; Sophie Jullien; Anand Krishnan; Eduardo Luis Lopez; Joško Markić; Ainara Mira-Iglesias; Hannah C Moore; Jocelyn Moyes; Lawrence Mwananyanda; D James Nokes; Faseeha Noordeen; Evangeline Obodai; Nandhini Palani; Candice Romero; Vahid Salimi; Ashish Satav; Euri Seo; Zakhar Shchomak; Rosalyn Singleton; Kirill Stolyarov; Sonia K Stoszek; Anne von Gottberg; Danielle Wurzel; Lay-Myint Yoshida; Chee Fu Yung; Heather J Zar; Harish Nair Journal: Lancet Date: 2022-05-19 Impact factor: 202.731
Authors: Sara Pischedda; Irene Rivero-Calle; Alberto Gómez-Carballa; Miriam Cebey-López; Ruth Barral-Arca; Jose Gómez-Rial; Jacobo Pardo-Seco; María-José Curras-Tuala; Sandra Viz-Lasheras; Xabier Bello; Ana B Crujeiras; Angel Diaz-Lagares; María Teresa González-López; Federico Martinón-Torres; Antonio Salas Journal: Front Immunol Date: 2022-05-10 Impact factor: 8.786
Authors: Peter F Wright; Anne G Hoen; J Dean Jarvis; Michael S Zens; Erika F Dade; Margaret R Karagas; Juliana Taube; Elizabeth B Brickley Journal: Ther Adv Infect Dis Date: 2022-05-27
Authors: Diana M Bowser; Katharine R Rowlands; Dhwani Hariharan; Raíssa M Gervasio; Lauren Buckley; Yara Halasa-Rappel; Elizabeth L Glaser; Christopher B Nelson; Donald S Shepard Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759
Authors: Mina Suh; Naimisha Movva; Xiaohui Jiang; Lauren C Bylsma; Heidi Reichert; Jon P Fryzek; Christopher B Nelson Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759